Filing Flows › Comparisons › TRAW vs ISCO
Traws Pharma vs International Stem Cell: TRAW and ISCO compared
Traws Pharma is the larger company: $2.7M of revenue in its latest quarter (Q2 2025) against $2.7M for International Stem Cell (Q2 2026). Traws Pharma is growing faster (48× against +9% a year earlier). International Stem Cell is more profitable, with an operating margin of -1.3% against -45.7%.
Where the money goes: TRAW and ISCO
Traws Pharma (TRAW) · Q2 2025
Traws Pharma, Q2 2025: revenue $2.7M (48× year over year), operating margin -45.7%, net loss $915K, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
International Stem Cell (ISCO) · Q2 2026
International Stem Cell, Q2 2026: revenue $2.7M (+9% year over year), operating margin -1.3%, net loss $71K, operating cash flow $167K. The chart follows the revenue to costs, profit and cash.
| Traws Pharma (TRAW) | International Stem Cell (ISCO) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q2 2026 |
| Revenue | $2.7M | $2.7M |
| Revenue growth, Y/Y | 48× | +9% |
| Operating margin | -45.7% | -1.3% |
| Net earnings | −$915K | −$71K |
| Net margin | -33.5% | -2.7% |
| Operating cash flow | −$6.0M | $167K |
| Free cash flow | — | $160K |
Where the revenue comes from
International Stem Cell
- Biomedical Market: $2.5M (94%)
- Anti Aging Skincare Market: $151K (6%)
Questions
Which is bigger, Traws Pharma or International Stem Cell?
Traws Pharma is the larger company: $2.7M of revenue in its latest quarter (Q2 2025) against $2.7M for International Stem Cell (Q2 2026).
Is Traws Pharma or International Stem Cell growing faster?
Traws Pharma is growing faster (48× against +9% a year earlier).
Which is more profitable, Traws Pharma or International Stem Cell?
International Stem Cell is more profitable, with an operating margin of -1.3% against -45.7%.
More: Traws Pharma earnings · how Traws Pharma makes money · International Stem Cell earnings · how International Stem Cell makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2025; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.